Back to search

Belgium· BE-AMP-SAM269832-00

Mitoxantrone Sandoz 2 mg/ml

A mitoxantrone product containing mitoxantrone hydrochloride, registered in Belgium by Sandoz. The same ATC class is registered in 14 of our 19 countries.

ATC L01DB07

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedMitoxantrone Sandoz 2 mg/mlATCL01DB07REGISTER NO.BE-AMP-SAM269832-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Mitoxantrone is registered in 14 of 19 countries.

Countries holding a registration under ATC L01DB07 (mitoxantrone), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Mitoxantrone · ATC L01DB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Mitoxantrone Hydrochloride
Manufacturer
Sandoz
Country
Belgium (BE)
ATC code
L01DB07
ATC class
Mitoxantrone
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0787804
  • be_apb
    2454742

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

405 interactions on record for mitoxantrone.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Mitoxantrone · interactions on record

405 records

  • 31 severe
  • 199 moderate
  • 15 minor
  • 160 info

Most severe, free to view

  • DolasetronA04AA04severe
  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mitoxantrone in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mitoxantrone products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Ebexantron
  • Bulgaria · Митоксантрон Ебеве
  • Germany · Mitoxantron Hexal, Novantron
  • Denmark · Mitoxantron "ebewe"
  • Estonia · Onkotrone
  • Spain · Mitoxantrona Accord, Novantrone
  • Finland · Mitoxantron Ebewe
  • France · Mitoxantrone Accord
  • United Kingdom (Northern Ireland) · Mitoxantrone Accord Healthcare, Onkotrone Injection
  • Greece · Mitoxan
  • Hungary · Onkotrone
  • Italy · Onkotrone
  • Lithuania · Onkotrone
  • Luxembourg · Mitoxantrone Sandoz
  • Latvia · Onkotrone
  • Malta · Onkotrone
  • Netherlands · Mitoxantron Accord, Mitoxantron Sandoz
  • Norway · Mitoxantron Ebewe
  • Poland · Mitoxantron Sandoz
  • Portugal · Mitoxantrona Pharmis, Mitoxantrone Baxter
  • Romania · Onkotrone
  • Sweden · Mitoxantron Ebewe
  • Slovenia · Onkotrone
  • Slovakia · Onkotrone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea5e55c5-6915-486d-9bf8-8e384e820adc
GET /v1/drugs/ea5e55c5-6915-486d-9bf8-8e384e820adc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Mitoxantrone Sandoz 2 mg/ml",
  "name_fr": "Mitoxantrone Sandoz 2 mg/ml",
  "name_nl": "Mitoxantrone Sandoz 2 mg/ml",
  "amp_code": "SAM269832-00",
  "strengths": [
    "2.3300",
    "2.0000",
    "0.0830",
    "8.0000",
    "0.4000"
  ],
  "pack_count": 3,
  "substances": [
    "Mitoxantrone Hydrochloride",
    "Mitoxantrone",
    "Sodium Acetate",
    "Sodium Chloride",
    "Sodium Sulfate Anhydrous"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Mitoxantrone",
  "authorisation_numbers": [
    "BE269832"
  ]
}

See everything about mitoxantrone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.